Re­jig­ging Mer­ck KGaA part­ner­ship, Eliot Forster gains full con­trol of the al­pha in F-star's con­stel­la­tion

Eliot Forster walked in­to this year’s JP Mor­gan con­fer­ence — his first since as­sum­ing the CEO seat at F-star — with a clear goal in mind: Talk to Mer­ck KGaA about get­ting its lead bis­pe­cif­ic an­ti­body back.

Four months lat­er, the sea­soned biotech en­tre­pre­neur is pleased to find FS118 ful­ly un­der his team’s con­trol as he piv­ots F-star away from a part­ner­ship mod­el in­to a more ma­ture, in­de­pen­dent play­er mak­ing its own calls in the clin­ic.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER